According to TipRanks.com, Syed has 0 stars on 0-5 stars ranking scale with an average return of -14.3% and a 36.1% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Coherus Biosciences, and Unity Biotechnology.
Currently, the analyst consensus on Amgen is a Hold with an average price target of $243.07.
Amgen’s market cap is currently $131.6B and has a P/E ratio of 22.93.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1980, California-based Amgen, Inc. is one of the world’s leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
Read More on AMGN: